AppMed Inc.
AppMed Inc. is a Canadian Health Canada-approved SaMD Class II company offering a web-based clinical platform for precision dosing, remote therapeutic drug monitoring, and medication adherence, serving healthcare organizations, clinicians, and patients across pain management, women's health, and mental health.
- Company typePrivate
- Founded2017
- HeadquartersLaval, Canada
- Headcount—
- GTM typeB2B
- OfferingSoftware
What AppMed Inc. does
AppMed Inc. is a privately held Canadian healthcare technology company headquartered in Laval, Quebec, founded in 2017. The company operates the AppMed platform, a web-based Software as a Medical Device (SaMD) that has been approved by Health Canada as a Class II medical device. The platform is purpose-built for medications with narrow therapeutic windows and consolidates three integrated modules—Dosage Optimization using validated pharmacokinetic/pharmacodynamic models with Bayesian algorithms, Dosage Monitoring through remote therapeutic drug monitoring (RTDM) with patient-reported outcomes and microsampling biomarkers, and Dosage Adherence via connected medication dispensing system devices—into a single clinical environment. It is deployed across three therapeutic areas: Pain Management (including opioid tapering and deprescribing), Women's Health (menopause and individualized HRT monitoring), and Mental Health (ADHD treatment optimization, schizophrenia monitoring, and depression protocols), with validated psychiatric instruments including ADHD-RS, Conners, BRIEF, PANSS, BPRS, PHQ-9, and GAD-7.
The platform is hosted on AWS Montreal infrastructure, with security designed in alignment with SOC 1, SOC 2 Type II, ISO 27001, ISO 27018, Quebec Law 25, and PIPEDA, and is positioned as a 100% Canadian solution. Customers include healthcare professionals, hospitals, pain clinics, mental health programs, research institutions, and pharmaceutical companies, with named clinical partners including Université de Montréal, McGill University Health Centre (MUHC), Hôpital Maisonneuve-Rosemont, Centre de recherche du CHU Sainte-Justine, and Hormonova Clinique. Patients access the platform directly through app.appmed.ca for health tracking, care team connectivity, self-collected microsamples, and patient-reported outcome submission.
AppMed generates revenue primarily through SaaS subscriptions to its clinical platform, supplemented by hardware distribution of Neoteryx Mitra VAMS microsampling devices and Harpera Microbiopsy Punch products as the exclusive Canadian distributor of Trajan Scientific and Medical. The go-to-market combines enterprise field sales targeted at healthcare organizations, channel partnerships including the Trajan distribution agreement, and a direct-to-consumer patient portal. Pricing is not publicly disclosed; customers are directed to request clinical demonstrations or volume quotes for microsampling products. The company is founder-controlled, with a multidisciplinary leadership team spanning clinical research, regulatory affairs, software validation, pharmacology, and health economics, and no external institutional investors have been disclosed.
AppMed Inc. firmographics
Firmographics- Name
- AppMed Inc.
- Legal name
- AppMed Inc.
- Website
- https://appmed.ai
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Short description
- AppMed Inc. is a Canadian Health Canada-approved SaMD Class II company offering a web-based clinical platform for precision dosing, remote therapeutic drug monitoring, and medication adherence, serving healthcare organizations, clinicians, and patients across pain management, women's health, and mental health.
- Ownership category
- akta.pro rank
AppMed Inc. industry classification
Industry- Product category
- Clinical Decision Support Software (Software as a Medical Device)
- NAICS
- Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software (HLACANAD)
- akta.pro secondary industries
- SaMD – Monitoring, Triage & Risk Stratification Software (HLACANAE), SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF), Women’s Health & Fertility Therapeutics (Digital) (HLACANAK), Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF)
Keywords
Where AppMed Inc. is headquartered
LocationHeadquarters
- HQ city
- Laval
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
AppMed Inc. business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain, Infrastructure
Revenue model
- SaaS Platform Subscription: Subscription-based access to the AppMed™ clinical platform for healthcare organizations, clinicians, and research institutions. Platform includes dosage optimization, remote monitoring, and adherence tracking capabilities. Pricing likely tiered by organization size or feature modules.
- Microsampling Products Distribution: Distribution of Neoteryx® Mitra® VAMS® microsampling devices and Harpera® skin biopsy products as exclusive Canadian distributor. Revenue from product sales to clinical sites, research institutions, and pharmaceutical companies.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
AppMed Inc. product offering
Product offeringCore offering
AppMed Inc. develops and sells AppMed™, a Health Canada approved Software as a Medical Device (SaMD) Class II web-based clinical platform that integrates three modules — Dosage Optimization (model-informed precision dosing via validated PK/PD and Bayesian algorithms), Dosage Monitoring (remote therapeutic drug monitoring with patient-reported outcomes and microsampling biomarkers), and Dosage Adherence (connected medication dispensing system tracking) — deployed across Pain Management, Women's Health, and Mental Health programs. The company also distributes Neoteryx® Mitra® VAMS® microsampling devices and Harpera® Microbiopsy products as the exclusive Canadian distributor for Trajan.
Product overview
AppMed Inc. offers AppMed™ as a unified Health Canada approved SaaMD Class II clinical digital platform combining three integrated solution modules — Dosage Optimization (model-informed precision dosing), Dosage Monitoring (remote therapeutic drug monitoring with patient-reported outcomes and microsampling), and Dosage Adherence (connected medication dispensing system monitoring) — deployed across three therapeutic areas: Pain Management (including opioid tapering and post-surgical monitoring), Women's Health (menopause/HRT care), and Mental Health (ADHD, schizophrenia, depression). The platform also distributes microsampling products including Mitra® VAMS® devices (exclusive Canadian distributor of Neoteryx® by Trajan) and Harpera® Microbiopsy devices for dermatology research.
Differentiator
Problem solved
Functional benefit
Products and services
- AppMed™ Platform Health Canada approved SaaMD Class II clinical digital platform that consolidates real-time patient-recorded data into comprehensive clinical profiles for healthcare professionals, clinicians, researchers, institutions, and partners, combining dosage optimization, continuous monitoring, and treatment adherence in a single environment.
- Dosage Optimization Solution Model-informed precision dosing module using validated pharmacokinetic and pharmacodynamic models with Bayesian PK/PD algorithms, enabling individualized and safer titration for medications with narrow therapeutic windows (including a Population PK/PD calculator for ADHD).
- Dosage Monitoring Solution Remote therapeutic drug monitoring and clinical assessment module that tracks treatment response continuously using patient-reported outcomes, therapeutic drug monitoring, microsampling biomarkers, and connected physiological devices.
- Dosage Adherence Solution Medication dispensing system monitoring module that tracks adherence via connected MDS devices, enables remote dose adjustments, and provides early intervention alerts before unplanned visits become necessary.
- Pain Management Program Therapeutic-area offering covering post-operative pain management, opioid tapering programs, deprescribing protocols, and chronic pain management with continuous pain assessments, adherence tracking, and MME-guided PRO surveillance for clinicians and healthcare organizations.
- Women's Health Program Therapeutic-area offering for menopause care and hormone replacement therapy management using continuous real-time symptoms and period tracking to guide individualized HRT treatment decisions and detect therapeutic drift.
- Mental Health Program Therapeutic-area offering for monitoring neurodivergent conditions including ADHD, schizophrenia, and depression using validated PRO tools (ADHD-RS, Conners, BRIEF, PANSS, BPRS, PHQ-9, GAD-7) and a population PK/PD calculator for real-time therapeutic decisions and antipsychotic TDM.
- Mitra® VAMS® Microsampling Devices Volumetric Absorptive Microsampling devices (VAMS) for at-home blood sample collection enabling therapeutic drug monitoring without clinic visits; Health Canada registered Class 1 DIV device, 120µL max volume, 99% sample acceptance rate, Hematocrit bias elimination, room-temperature stability up to one month. Available formats include sample pouches, microsampling kits (with prepaid return envelopes), 96-Autorack™ for laboratory automation, and long-term storage solutions.
- Harpera® Microbiopsy Punch Scarless skin biopsy device using laser-cut stainless steel technology for dermatology research and clinical applications, with ergonomic handle, safety cap, and controlled punch actuation for reliable and reproducible sample collection in longitudinal studies.
Quantifiable outcome
- 96% surge in opioid toxicity deaths during COVID-19 pandemic driven by disrupted monitoring and reduced access to care for chronic pain patients
- +9 more outcomes
Companies that use AppMed Inc.
Customer profileNamed customers3 records
Segments8 records
Ideal customer profiles3 records
AppMed Inc. technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature8 records
AppMed Inc. partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and minor.
- Université de MontréalcoreAcademic research collaboration in clinical digital health and precision medicine. Logo displayed in partner ecosystem section indicating formal collaborative relationship in research and development of digital health solutions.
- Centre de recherche du Centre hospitalier universitaire Sainte-Justine (CR-CHU Sainte-Justine)coreHealthcare research collaboration with major pediatric teaching hospital in Montreal. Logo displayed in partner ecosystem section indicating clinical research partnership.
- McGill University Health Centre (MUHC)coreClinical partnership with major McGill University-affiliated hospital network. Logo displayed in partner ecosystem section indicating collaborative healthcare research and implementation.
- Hôpital Maisonneuve-Rosemont (HMR)coreClinical collaboration with affiliated teaching hospital. Logo displayed in partner ecosystem section indicating therapeutic monitoring program partnership.
- Hormonova CliniquecoreSpecialized women's health clinic partnership for hormone replacement therapy monitoring and menopause care programs. Logo displayed in partner ecosystem.
- Neoteryx® by Trajan Scientific and MedicalcoreExclusive Canadian distributor agreement for Neoteryx® microsampling products including Mitra® VAMS® devices, hemaPEN®, and related products. AppMed serves as the exclusive Canadian channel partner for Trajan's microsampling technology. Also distributes Harpera® Microbiopsy Punch products.
- DivocominorPartner logo displayed in partner ecosystem section. Nature of partnership not explicitly detailed in available source material.
- LOKQualiTminorPartner logo displayed in partner ecosystem section. Nature of partnership not explicitly detailed in available source material.
- C3i (Centre de consultation et d'investigation)minorPartner logo displayed in partner ecosystem section. Nature of partnership not explicitly detailed in available source material.
- ThessminorPartner logo displayed in partner ecosystem section. Nature of partnership not explicitly detailed in available source material.
- Cedar StrategiesminorPartner logo displayed in partner ecosystem section. Nature of partnership not explicitly detailed in available source material.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
AppMed Inc. competitors and assessment
Company assessmentEmerging players
- Mahana Therapeutics: Mahana Therapeutics develops FDA-authorized prescription digital therapeutics for chronic conditions including IBS and tinnitus. Comparable as a regulated digital therapeutics company pursuing therapeutic area specialization with clinical evidence requirements.
- Medisafe: Medisafe is a digital medication adherence platform with connected pill bottles and patient engagement tools. Comparable to AppMed's adherence module but without PK/PD dosing optimization or SaMD regulatory classification.
- Big Health: Big Health provides digital therapeutics for insomnia (Sleepio) and anxiety (Daylight), with FDA clearance as digital therapeutics. Comparable as a digital therapeutic player in mental health, though focused on sleep/anxiety versus AppMed's ADHD/schizophrenia focus.
Others
- Trajan Scientific and Medical: Trajan is the manufacturer of Neoteryx® Mitra® VAMS® microsampling technology and Harpera® Microbiopsy devices. AppMed is Trajan's exclusive Canadian distributor, making Trajan both a supplier and a strategic partner for the hardware component of AppMed's offering.
- Cedar Strategies: Listed as a partner/consulting collaborator in AppMed's ecosystem. Although direct comparability is limited, they are an ecosystem participant supporting the company.
Broad incumbents
- Teva Pharmaceuticals (Digihaler System): Teva's Digihaler system combines connected inhalers with software for asthma/COPD adherence tracking. Comparable as a large pharmaceutical player integrating connected hardware and software for adherence and remote monitoring in chronic conditions.
- Oracle Health (formerly Cerner): Oracle Health provides enterprise EHR and population health platforms used by major health systems. Comparable as a broad incumbent in clinical decision support with potential to bundle precision dosing functionality that competes with AppMed's SaMD.
- Epic Systems (Beaker): Epic's Beaker laboratory information system and broader EHR platform dominate hospital clinical workflows and decision support in North America. Represents both a potential integration partner and competitive threat as Epic adds precision medicine capabilities to its enterprise platform.
Direct peers
- InsightRX: InsightRX provides model-informed precision dosing software for clinicians, leveraging patient-specific factors and therapeutic drug monitoring to individualize medication dosing. Highly comparable to AppMed's platform for both dosing optimization and TDM workflows.
- DoseMeRx: DoseMeRx is a model-informed precision dosing SaaS platform using Bayesian PK/PD algorithms to optimize dosing for antibiotics, anticoagulants, and other narrow therapeutic window drugs. Directly comparable to AppMed's dosage optimization module, though focused on hospital pharmacy workflows.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
AppMed Inc. social profiles
Digital presenceAppMed Inc. compliance and trust
Trust signalCompliance6 records
AppMed Inc. financial estimates
Financial estimateRevenue estimate
Valuation estimate
AppMed Inc. leadership team
Management profileNumber of profiles
Profiles7 records
AppMed Inc. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AppMed Inc. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AppMed Inc.
What does AppMed Inc. do?
AppMed Inc. develops and sells AppMed™, a Health Canada approved Software as a Medical Device (SaMD) Class II web-based clinical platform that integrates three modules — Dosage Optimization (model-informed precision dosing via validated PK/PD and Bayesian algorithms), Dosage Monitoring (remote therapeutic drug monitoring with patient-reported outcomes and microsampling biomarkers), and Dosage Adherence (connected medication dispensing system tracking) — deployed across Pain Management, Women's Health, and Mental Health programs. The company also distributes Neoteryx® Mitra® VAMS® microsampling devices and Harpera® Microbiopsy products as the exclusive Canadian distributor for Trajan.
Is AppMed Inc. a public or private company?
AppMed Inc. is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was AppMed Inc. founded?
AppMed Inc. was founded in 2017.
Where is AppMed Inc. based?
AppMed Inc. is headquartered in Laval, Canada, in the North America region.
How does AppMed Inc. make money?
Two revenue lines are on record. SaaS Platform Subscription is the primary driver. The others are microsampling Products Distribution.
Who are AppMed Inc.'s main competitors?
Emerging players on record are Mahana Therapeutics, Medisafe and Big Health. Others are Trajan Scientific and Medical and Cedar Strategies. Broad incumbents are Teva Pharmaceuticals (Digihaler System), Oracle Health (formerly Cerner) and Epic Systems (Beaker). Direct peers are InsightRX and DoseMeRx.
Does AppMed Inc. have an API?
No public API is recorded for AppMed Inc..
What industry is AppMed Inc. in?
AppMed Inc.'s product category is Clinical Decision Support Software (Software as a Medical Device). Its primary akta.pro industry code is HLACANAD, Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software, with a secondary code of HLACANAE, SaMD – Monitoring, Triage & Risk Stratification Software. Its NAICS code is 62151 and its SIC code is 7372.